These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 5910365)

  • 21. Treatment of advanced adenocarcinoma of the endometrium with melphalan, 5-fluorouracil, and medroxyprogesterone acetate: a preliminary study.
    Cohen CJ; Deppe G; Bruckner HW
    Obstet Gynecol; 1977 Oct; 50(4):415-7. PubMed ID: 904803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Progestational hormones in endometrial carcinoma].
    Corres Innes J; Zazueta Valadez F; Vela Lugo C
    Ginecol Obstet Mex; 1967 Sep; 22(131):1193-203. PubMed ID: 5602498
    [No Abstract]   [Full Text] [Related]  

  • 23. Chromatin analysis in human endometrial adenocarcinoma before and after treatment with 6-methyl-17-hydroxyprogesterone acetate (MPA).
    Barni S; Novelli G; Zanoio L; Gerzeli G; Vecchietti G
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1981; 37(2):167-77. PubMed ID: 6115504
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate.
    Bruckner HW; Deppe G
    Obstet Gynecol; 1977 Jul; 50(1 Suppl):10s-12s. PubMed ID: 876531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant progesterone therapy for stage I endometrial carcinoma.
    Malkasian GD; Burĕs J
    Int J Gynaecol Obstet; 1978; 16(1):48-9. PubMed ID: 32089
    [No Abstract]   [Full Text] [Related]  

  • 26. The possible mechanisms of action of progestins on endometrial adenocarcinoma.
    Anderson DG
    Am J Obstet Gynecol; 1972 May; 113(2):195-211. PubMed ID: 4112650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medroxyprogesterone acetate release from silastic devices as replacement for local irradiation by radium tubes in preoperative intrauterine packing for endometrial adenocarcinoma: a preliminary study.
    Decoster JM; Bonte J; Marcq A
    Gynecol Oncol; 1977 Jun; 5(2):189-95. PubMed ID: 881131
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of adenocarcinomas of the uterine body with medroxyprogesterone].
    Bonte J; Drochmans A; Lassance M
    Gynecol Obstet (Paris); 1966; 65(2):179-85. PubMed ID: 5942790
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effects of medroxyprogesterone (MAP) therapy on the DNA content in adenocarcinoma of the human endometrium].
    Vecchietti G; Gerzeli G; Zanoio L; Novelli GG; Barni S
    Minerva Ginecol; 1979; 31(7-8):597-603. PubMed ID: 481819
    [No Abstract]   [Full Text] [Related]  

  • 30. Use of progestational agents in the management of metastatic carcinoma of the endometrium.
    Kistner RW; Griffiths CT
    Clin Obstet Gynecol; 1968 Jun; 11(2):439-56. PubMed ID: 4879374
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment and prognosis of endometrial cancer.
    Whitfield CR
    Clin Obstet Gynaecol; 1976 Aug; 3(2):407-23. PubMed ID: 1009728
    [No Abstract]   [Full Text] [Related]  

  • 32. Hormonal treatment of recurrent endometrial carcinoma. Report of a case.
    Nilsen PA
    J Obstet Gynaecol Br Commonw; 1968 Jan; 75(1):99-100. PubMed ID: 5635249
    [No Abstract]   [Full Text] [Related]  

  • 33. Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer.
    Lewis GC; Slack NH; Mortel R; Bross ID
    Gynecol Oncol; 1974 Aug; 2(2-3):368-76. PubMed ID: 4616883
    [No Abstract]   [Full Text] [Related]  

  • 34. Medroxyprogesterone in the management of primary and recurrent or metastatic uterine adenocarcinoma.
    Bonte J
    Acta Obstet Gynecol Scand Suppl; 1972; 19():21-4. PubMed ID: 4508284
    [No Abstract]   [Full Text] [Related]  

  • 35. [Therapy of adenocarcinoma of the endometrium with synthetic progestogens].
    Lanza A; Fedele M; Renzetti ME; Ferraris G
    Minerva Ginecol; 1981 Oct; 33(10):917-36. PubMed ID: 7031519
    [No Abstract]   [Full Text] [Related]  

  • 36. [Hormonal treatment of uterine corpus carcinoma (our personal experience)].
    Zielonka I; Kwaśniewska-Rokicińska C
    Nowotwory; 1977; 27(1):67-71. PubMed ID: 558605
    [No Abstract]   [Full Text] [Related]  

  • 37. Endometrial carcinoma insensitive to progestin and cytotoxic chemotherapy may respond to tamoxifen.
    Kauppila A; Vihko R
    Acta Obstet Gynecol Scand; 1981; 60(6):589-90. PubMed ID: 6461159
    [No Abstract]   [Full Text] [Related]  

  • 38. Oral progestin therapy for metastatic adenocarcinoma of the endometrium.
    Puckett TG; Merrill JA
    J Okla State Med Assoc; 1967 Sep; 60(9):506-11. PubMed ID: 6076025
    [No Abstract]   [Full Text] [Related]  

  • 39. Tamoxifen and aminoglutethimide in the management of patients with advanced endometrial carcinoma not responsive to medroxyprogesterone.
    Quinn MA; Campbell JJ; Murray R; Pepperell RJ
    Aust N Z J Obstet Gynaecol; 1981 Nov; 21(4):226-9. PubMed ID: 6951563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of progestational agents in endometrial adenocarcinoma.
    Rozier JC; Underwood PB
    Obstet Gynecol; 1974 Jul; 44(1):60-4. PubMed ID: 4834800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.